Ceftriaxone is a long-acting, broad-spectrum cephalosporin that produces antibacterial effects by inhibiting the synthesis of cell walls. It has a strong bactericidal effect on both Gram-positive and Gram-negative bacteria. It is highly stable to β-lactamase (including penicillinase and cephalosporinase). In vitro and clinical trials have shown that ceftriaxone sodium has high antibacterial activity against the following Gram-negative bacilli: Escherichia coli, Klebsiella, Proteus mirabilis, indole-positive Proteus, Salmonella, Shigella and other r/Enterobacteriaceae and Haemophilus influenzae; it also has good antibacterial effects on Gram-negative cocci such as meningococci and gonococci; Gram-positive cocci such as pneumococci, Streptococcus pyogenes, Streptococcus viridans, and Streptococcus bovis are all sensitive to this product; it also has a certain antibacterial effect on Staphylococcus aureus, but the antibacterial effect is poorer than the above Gram-positive cocci. Pseudomonas aeruginosa and Acinetobacter are less sensitive to this product. It also has antibacterial activity against some anaerobic bacteria such as Bacteroides fragilis, Clostridium, and Peptococcus.

This product is a first-generation cephalosporin with a broad antibacterial spectrum and strong activity against Gram-positive bacteria. Penicillinase-producing and non-penicillinase-producing Staphylococcus aureus, coagulase-negative Staphylococcus, Streptococcus pyogenes, Streptococcus pneumoniae, Group B hemolytic Streptococcus, Streptococcus viridans, Staphylococcus epidermidis, Corynebacterium diphtheriae, and Bacillus anthracis are all quite sensitive to this product. Enterococci, methicillin-resistant Staphylococcus, Listeria, and Nocardia are resistant. Haemophilus influenzae, Neisseria meningitidis, Moraxella catarrhalis, and Neisseria gonorrhoeae are highly sensitive to this product. Some strains of Escherichia coli, Klebsiella, Salmonella, Shigella, and Proteus are moderately sensitive to this product, while most of the other Gram-negative rods are resistant. Gram-positive anaerobic bacteria are sensitive to this product, and Bacteroides fragilis is resistant to this product. This product mainly inhibits the synthesis of bacterial cell walls.

This product is a third-generation cephalosporin antibiotic for injection. It exerts a bactericidal effect by inhibiting the synthesis of bacterial cell walls. This product is mainly effective against a variety of G and G- bacteria and anaerobic bacteria, and is sensitive to the following pathogens: such as Staphylococcus aureus (excluding methicillin-resistant strains), Streptococcus, Pneumococcus, Neisseria gonorrhoeae (including strains producing β-lactamase), Neisseria meningitidis, Branhamella catarrhalis, Escherichia coli, Shigella, Salmonella, Citrobacter, Klebsiella, Proteus vulgaris, Providencia, Morganella morganii, Haemophilus influenzae, Corynebacterium. This product is stable to β-lactamase produced by most bacteria. This product is ineffective against Bacteroides, Acinetobacter, Enterococcus faecalis, Listeria, Mycoplasma, and Chlamydia.

It is relatively stable against beta-lactamase produced by Staphylococcus aureus and has a strong antibacterial effect on Gram-positive bacteria. Its activity against penicillinase-producing Staphylococcus aureus, group A hemolytic streptococci, grass-green streptococci and Staphylococcus epidermidis is the same as that of cefoperazone, and its antibacterial effect against non-enzyme-producing Staphylococcus aureus and pneumococci is 2 to 4 times stronger than that of cefoperazone. Its activity against Gram-negative bacilli, including Escherichia coli and Klebsiella pneumoniae, is stronger than that of cefoperazone, and is similar to that of cefoperazone. Its activity against Proteus mirabilis, Salmonella and Shigella is stronger than that of cefoperazone. 2.9 to 8 mg/L of cefaclor can inhibit all influenza bacilli, including ampicillin-resistant strains. Moraxella catarrhalis and gonococci are sensitive to this product. Indole-positive Proteus, Serratia, Acinetobacter and Pseudomonas aeruginosa are all resistant to cefoperazone.

It has a strong effect of dissolving mucus and can break down the polysaccharide cellulose in sputum and thin the sputum. It inhibits the synthesis of glycoproteins by goblet cells and mucous glands to reduce the sialic acid in sputum, reduce the viscosity of sputum, and facilitate discharge.